KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Free Cash Flow (2016 - 2025)

Neogenomics (NEO) has disclosed Free Cash Flow for 16 consecutive years, with $18.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow rose 163.46% year-over-year to $18.8 million, compared with a TTM value of $3.5 million through Dec 2025, up 110.33%, and an annual FY2025 reading of $3.5 million, up 110.33% over the prior year.
  • Free Cash Flow was $18.8 million for Q4 2025 at Neogenomics, up from $570000.0 in the prior quarter.
  • Across five years, Free Cash Flow topped out at $27.2 million in Q3 2021 and bottomed at -$81.7 million in Q4 2021.
  • Average Free Cash Flow over 5 years is -$11.0 million, with a median of -$7.3 million recorded in 2022.
  • The sharpest move saw Free Cash Flow crashed 23434.11% in 2022, then surged 928.99% in 2023.
  • Year by year, Free Cash Flow stood at -$81.7 million in 2021, then surged by 94.83% to -$4.2 million in 2022, then crashed by 144.31% to -$10.3 million in 2023, then tumbled by 186.23% to -$29.6 million in 2024, then skyrocketed by 163.46% to $18.8 million in 2025.
  • Business Quant data shows Free Cash Flow for NEO at $18.8 million in Q4 2025, $570000.0 in Q3 2025, and $14.0 million in Q2 2025.